Biotech firm OncoGenex sees stock sink 40% after unsuccessful clinical trial by Clare McGrane on August 16, 2016August 16, 2016 at 10:57 am OncoGenex, a pharmaceutical firm based in Bothell, Wash., announced today an unsuccessful end to their phase 3 clinical trial of an experimental cancer drug. The company’s stock fell 40 percent as… Read More